Etiology | Number (%) | Age (years) | Education level | Baseline MMSE value |
---|---|---|---|---|
Infectious entities | 39 (26.2%) | 56.1 ± 14.5 | 6, 9, 22 | 13.1 ± 4.6 |
Creutzfeldt-Jakob disease | 20 (13.4%) | Â | Â | Â |
Neurosyphilis | 8 (5.4%) | Â | Â | Â |
Other infections entities | 11 (7.4%) | Â | Â | Â |
Neurodegenerative entities | 31 (20.8%) | 68.4 ± 10.8 | 8, 6, 16 | 11.2 ± 4.0 |
Alzheimer’s disease | 17 (11.4%) |  |  |  |
Dementia with Lewy body | 8 (5.4%) | Â | Â | Â |
Neuronal intranuclear inclusion disease | 4 (2.7%) | Â | Â | Â |
Frontotemporal lobar degeneration | 2 (1.4%) | Â | Â | Â |
Toxic/metabolic entities | 25 (16.8%) | 53.1 ± 12.7 | 3, 3, 18 | 12.4 ± 5.5 |
Carbon monoxide poisoning | 12 (8.1%) | Â | Â | Â |
Heroin poisoning | 1 (0.7%) | Â | Â | Â |
Dichloroethane poisoning | 1 (0.7%) | Â | Â | Â |
Alcohol poisoning | 2 (1.3%) | Â | Â | Â |
Other toxic entities | 2 (1.3%) | Â | Â | Â |
Mitochondrial encephalopathy | 2 (1.3%) | Â | Â | Â |
Wernicke encephalopathy | 1 (0.7%) | Â | Â | Â |
Hashimoto encephalopathy | 1 (0.7%) | Â | Â | Â |
Radiation encephalopathy | 1 (0.7%) | Â | Â | Â |
Other metabolic entities | 2 (1.3%) | Â | Â | Â |
Inflammatory entities | 15 (10.1%) | 51.1 ± 13.7 | 1, 5, 8 | 13.8 ± 4.6 |
Anti-AMPA2 receptor encephalitis | 3 (2.0%) | Â | Â | Â |
Anti-LG1 receptor encephalitis | 3 (2.0%) | Â | Â | Â |
Limbic encephalitis | 2 (1.3%) | Â | Â | Â |
Anti-GABAB receptor encephalitis | 1 (0.7%) | Â | Â | Â |
Central demyelinating disease | 2 (1.3%) | Â | Â | Â |
Sjogren’s syndrome with central involvement | 1 (0.7%) |  |  |  |
Other inflammatory entities | 3 (2.0%) | Â | Â | Â |
Vascular entities | 13 (8.7%) | 63.1 ± 12.8 | 1, 5, 7 | 14.6 ± 4.3 |
Other entities | 11 (7.4%) | 55.0 ± 17.4 | 2, 3, 6 | 15.0 ± 3.6 |
Mixed entities | 5 (3.4%) | 72.6 ± 9.1 | 1, 3, 1 | 12.2 ± 6.5 |
Neoplastic entities | 5 (3.4%) | 53.8 ± 13.1 | 0, 3, 2 | 14.3 ± 2.1 |
Undetermined entities | 5 (3.4%) | 54.8 ± 27.1 | 1, 1, 3 | 16.0 ± 1.0 |